Rebiotix’s microbiota-based RBX2660 could secure FDA approval to reduce C. difficile infection (CDI) recurrence, following a positive vote from the agency’s advisory committee. The FDA is due to rule on the live biotherapeutic — made from human stool — by mid-November, positioning it to potentially become the first microbiome-based drug to get the regulatory nod in the USA…

Para acessar a publicação na íntegra clique aqui

Fonte: 786 | november 2022 | volume 21 news in brief www.nature.com/nrd